Defining the relationships between diet, energy balance, hormones, tobacco, and cancer
Investigators in the Metabolic Epidemiology Branch (MEB) conduct interdisciplinary research to understand the role of metabolic and lifestyle exposures in causing and preventing cancer. Some of the potentially modifiable exposures we study include diet, hormones, physical activity, and tobacco. We study how these exposures relate to a broad variety of cancers with researchers focusing on breast, colon, endometrium, esophagus, liver, stomach, ovary, pancreas, prostate, and testis. We use traditional epidemiological methods combined with a variety of molecular methods including genomic analysis, metabolomics, microbiomics, and molecular pathology.
MEB’s research mission is to conduct collaborative high-impact epidemiological research on metabolic and lifestyle causes of cancer that will guide prevention and early intervention strategies worldwide.
We define causal relationships between diet, energy balance, hormones, tobacco, and cancer. Learn more about MEB research areas.
Training and mentoring the next generation of scientists is a key component of MEB’s mission. We provide research training for tenure-track investigators, post-doctoral fellows, doctoral students, masters and post-baccalaureate students, visiting fellows, and summer interns. Meet the current MEB fellows and find out about our research training opportunities.
The Upper Gastrointestinal Cancer Research Group fosters the exchange of ideas and expertise on UGI cancers among investigators from DCEG, NCI, and the extramural community.
MEB investigators develop Web-based instruments, software tools, and other resources to support epidemiological and translational research. Find out more about MEB tools, methods and resources.
Abnet CC, et al. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 2018.
Cook MB, et al. Cancer incidence and mortality risks in a large U.S. Barrett's oesophagus cohort. Gut 2018.
Michels KA, et al. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol 2018; Epub Jan 18